UPDATED: FDA advisors recommend against approving Eli Lilly's PD-1, casting shadow over future of China-made cancer drugs - Endpoints News
- UPDATED: FDA advisors recommend against approving Eli Lilly's PD-1, casting shadow over future of China-made cancer drugs Endpoints News
- FDA committee votes against Eli Lilly cancer treatment over concerns trials conducted only in China CNBC
- FDA Panel Rejects Lilly’s Cancer Drug Tested Only in China The New York Times
- Thumbs down on Lilly, Innovent China trial for lung cancer drug Tyvyt, says FDA AdComm FiercePharma
- FDA Raises Concerns About China-Developed Drugs The Wall Street Journal
- View Full Coverage on Google News